Room 180, Stanford Law School

About the Event: As part of health care reform, a faster FDA approval process for biosimilar drugs (generic versions of drugs made by biological processes involving recombinant DNA technology) was created. This law also set up new rules for patent litigation involving those drugs. The new rules may influence the practical value of patents on biologic drugs and which drugs biotechs choose to develop and to market.

REGISTER HERE.
Free and Open to the Public
1.5 hours CLE credit will be offered.
Food and drinks will be served.
The panelists will be:

Robin Cooper Feldman, Professor of Law; Director, Law and Bioscience Project, UC Hastings College of the Law
Jennifer Flory, Intellectual Property Counsel, Hospira
Bruce Leicher, Senior Vice President and General Counsel, Momenta Pharmaceuticals, Inc.
Gary Loeb, Vice President, Intellectual Property, Genentech
Jessica Wolff, Partner, Intellectual Property Group, Cooley LLP

Registration Information: Registration for this event is complimentary. Please register your attendance by clicking here.

Sponsored by the Center for Law and the Biosciences and Cooley LLP.